Header Image
22. Chronic pain / muscle tension in ADHD

Sitemap

22. Chronic pain / muscle tension in ADHD

Author: Ulrich Brennecke
Review (March 2024): Dipl.-Psych. Waldemar Zdero
Completely revised: December 2024

1. Chronic pain and ADHD

People with ADHD often show increased sensitivity to pain. High ADHD scores correlated with increased pain1
ADHD also correlates with chronic pain.23 Children with ADHD had a 45% increased risk of weekly pain. Hyperactivity/impulsivity had a 133% increased risk of frequent pain, inattention a 17% increased risk. Multiple pains were more common in girls with hyperactivity than in boys with hyperactivity (51.4% vs. 27.9%). 25% of girls with ADHD-C and 20% of boys with ADHD-C had weekly headaches and/or abdominal pain, compared with 11% to 13% of children without these symptoms (+127% to +53%).4
Children and adolescents suffer from chronic pain

  • to 20 %5
  • to 20.8 % (meta-analysis, k = 19, n = 1,043,878)6
    • Headache and skeletal muscle pain: 25.7 % (meta-analysis, k = 19, n = 1,043,878)6
    • Chronic pain and pain intensity in patients with ADHD are associated with muscular dysregulation.7
  • The prevalence rates of chronic pain in children and adolescents in a meta-analysis varied considerably:8
    • Headaches: 8 % to 83 %
    • Abdominal pain: 4 % to 53 %
    • Back pain: 14 % to 24 %
    • Skeletal muscle pain: 4% to 40%
    • multiple pain: 4 % to 49 %
    • other pain: 5 % to 88 %.

Similar symptoms are increased sensitivity to stress and increased sensitivity to punishment. See also Emotional dysregulation.

Girls are more likely to have chronic pain than boys, except for back pain and skeletal muscle pain (meta-analysis, k = 19, n = 1,043,878).6
Of 100 women with ADHD or ASD, 76% reported chronic pain.9 Chronic widespread pain (CWP), the main symptom of fibromyalgia, was almost twice as common in ADHD (39%) as in ASD.
The most frequently mentioned painful areas of the body were

  • Lower back (47 %)
  • Neck (37 %)
  • Shoulder (35 %)
  • Head (32 %, related to ADHD)
  • Stomach (30 %)
  • Arms / hands (30 %)
  • Upper back (27 %)
  • Knee (27 %)
  • Hip / thigh (18 %)
  • Calves / feet (16 %)
  • Breast (4 %)

ADHD correlates with an increased incidence of10

  • Fibromyalgia11
  • chronic pain in the lower back12
  • idiopathic orofacial pain 13
  • chronic abdominal pain9
  • Burning mouth syndrome
    • 92.2% of persons with ADHD showed ADHD14

Pain is associated with reduced tonic dopamine firing, which causes increased phasic dopamine firing in the nucleus accumbens.15 This is consistent with Grace’s model of decreased tonic and increased phasic dopamine firing in ADHD. See also Tonic and phasic dopamine in explanatory models for ADHD In the section Dopamine in the chapter Neurological aspects.
People with chronic pain show reduced responsiveness within the mesolimbic dopamine system to meaningful stimuli, reduced D2 receptor binding, reduced presynaptic dopamine activity in the striatum at rest and after an acute pain stimulus.16 In animals, chronic pain leads to decreased c-Fos activation in the VTA, decreased total dopamine levels and decreased D2 receptors in the striatum.16
Conversely, a reduction of dopamine in the brain by acute depletion of the dopamine precursors phenylalanine and tyrosine caused increased subjective pain sensitivity (the degree to which pain was perceived as unpleasant) without altering the sensory perception of pain.17
In 6-OHDA mice, in which dopamine synthesis is chemically damaged and which thus represent an ADHD animal model, an increased sensitivity to pain was found. The pain sensitivity was presumably mediated by α- and β-adrenergic and D2/D3 receptors. Atomoxetine18 such as MPH19 was able to reduce the increased pain sensitivity in ADHD.
Stimulation of the substantia nigra, one of the two most important sources of dopamine in the brain, causes pain relief by activating spinal cord neurons via dopaminergic signaling pathways.202122 Painful stimuli cause a release of dopamine in the dorsolateral striatum, which correlates with the subjective perception of pain intensity. The ventral striatum is also clearly associated with the emotional dimension of the human pain process and the expectation of pain.23
Increased sensitivity to pain correlated with certain dopaminergic gene variants (DAT1 and MAO-A, but not DRD4).24

In children with chronic pain (without headaches) an ADHD prevalence of 15 to 25 %, i.e. 2 to 5 times higher (meta-analysis).25
72.5% of adults referred to a pain clinic for chronic pain and a probable somatic syndrome disorder met the diagnostic criteria for ADHD.26 Of 60 adults with chronic non-specific lower back pain, 31.5% had ADHD.12
Psychiatric patients with chronic pain show a higher prevalence of ADHD than psychiatric patients without chronic pain.7
Children with ADHD showed a prevalence of chronic pain of up to 66% (at least weekly pain for more than 3 months). Stimulant treatment reduced the rate of chronic pain. Another study found a reduced perception of pain in adolescents with ADHD, which disappeared with stimulant treatment.25
Of young women with ADHD and/or ASD, 76.6%9 and 75.9% reported chronic pain, respectively, compared to 45.7% of unaffected young women27.
80% of the people with ADHD studied reported chronic pain.28

A population study over 15 years found significantly higher rates of various pain conditions in children with ADHD prior to their ADHD diagnosis:29

  • Headaches (+ 16 %)
  • Earache (+ 30 %)
  • Sore throat (+ 8 %)
  • Sprains and strains (+ 23 %)
  • more frequent use of painkillers
    • Paracetamol (+ 19 %)
    • Ibuprofen (+ 37 %)

One study found ADHD in 25 of 30 patients with refractory orofacial pain (83.3%; women: 20).30
ADHD was associated with a 32% increased risk of migraine, while the risk of tension headaches was unchanged.3132 Children with migraine had a 2.6-fold risk of ADHD, while the prevalence of migraine in children in general was 3.76%. Migraines correlated particularly with hyperactivity and impulsivity, not inattention.33 Children with ADHD have a 2.6-fold risk of migraine in ADHD, whereas the prevalence of migraine in children in general was 9.9% in this study32

In Parkinson’s disease, which is also characterized by dopamine deficiency, 30 to 50 % of people with ADHD suffer from increased sensitivity to pain.34 This can be improved by dopaminergic medication35, e.g. levodopa or deep brain stimulation.36
Conversely, the perception of pain is reduced in schizophrenia, which is associated with increased dopamine levels.37

2. Axial pain and ADHD

Chronic pain in patients with ADHD is characterized by widespread and axial pain that starts early. This “ADHD pain” is qualitatively different from chronic pain in patients without ADHD.7
Axial pain occurred in 86.6% of persons with ADHD, in 50% of those not diagnosed with ADHD, and in 21.4% of those who also did not have subclinical ADHD.
People with subclinical ADHD showed the same muscular dysregulation as people with ADHD.7
While ADHD is a predictor of “axial pain”, affective disorders, anxiety disorders or personality disorders were not.7

The axial muscles are:

  • Head and neck muscles
  • Spinal muscles
  • Other trunk muscles
  • Pelvic floor muscles

Axial muscles regulate and control posture and are constantly used to maintain the naturally unstable upright position. Muscular dysregulation has a significant impact here and could lead to high muscle tone with consequent widespread pain and lower back pain38

  • Erector spinae
  • Latissimus dorsi
  • Iliopsoas
    • connects the lumbar spine with the lower limbs
    • Iliopsoas spasms can increase lumbar lordosis and lumbar pain39

Gene variants that correlate with neck or shoulder pain causally increase the risk of ADHD.40

3. Increased muscle tension in ADHD

ADHD is often associated with increased muscle tension. This is not an expression of hyperactivity or a fundamental motor dysfunction. There are high-performance athletes with ADHD; they are unlikely to have severe motor dysfunction. Nevertheless, increased muscle tension can also be observed in them.

Muscle tension, especially in the shoulder/neck area, occurs much more frequently with ADHD.
An orthopaedist explained to us that during sleep, the muscles further away from the trunk (spine) relax first, while those at the spine relax last. These need undisturbed deep sleep in order to relax. Accordingly, muscle tension could also be a consequence of impaired sleep in ADHD.
One study found that computer work and sleep problems correlated with chronic shoulder and neck pain.41

MPH can help with increased muscle tension.42
Our impression in the ADxS forum is that increased muscle tension is reported more frequently with lisdexamfetamine.

With regard to fibromyalgia, which is often associated with greatly increased muscle tension, helpful treatment with very low doses of naltrexone (0.5 to 4.5 mg instead of the usual 150 mg) has been reported. The treatment is said to be virtually free of side effects.4344454647 Naltrexone is a long-acting competitive opioid antagonist that is also used to treat alcohol and opioid dependence. One person with ADHD told us that the low-dose naltrexone also helped with the ADHD symptoms.
Paracetamol was repeatedly mentioned as a treatment option.
Magnesium is also helpful.
Myotonolytics (e.g. methocarbamol, tolperisone, tetrazepam, flupirtine, tizanidine, baclofen, pridinol, eperisone or methocarbamol) have a muscle-relaxing effect by inhibiting polysynaptic reflex conduction in the spinal cord and in subcortical centers. However, they are less suitable for long-term use and have significant side effects. Tizanidine and cyclobenzaprine have a sedative effect and can help with existing sleep problems.48 Methocarbamol and metaxalone are slightly less sedating, but probably also less effective. Dizziness and drowsiness are reported with all myotonolytics.

4. Medication for chronic pain

4.1. ADHD medication reduces chronic pain associated with ADHD

MPH can remedy the increased sensitivity to pain in people with ADHD.4930135051
Atomoxetine5253 54 and guanfacine55 have also been shown to reduce chronic pain in people with ADHD. Clonidine, like guanfacine an alpha-adrenoceptor agonist, is helpful for ADHD and chronic pain.
US President John F. Kennedy is said to have had ADHD.56 Kennedy also suffered from chronic lower back pain, for which he successfully took amphetamine medication.57

31.8% of patients with various types of chronic pain who were referred to a psychiatrist in a pain clinic were diagnosed with ADHD. 21 of them received ADHD medication (methylphenidate and/or atomoxetine). ADHD symptoms improved in 20 of the 21 (95.5%). In 14 out of 21 (66.7 %), their pain symptoms improved at the same time, on average by 4.6 points (64.7 %) on the Pain Numerical Rating Scale (NRS). Among the 7 medicated patients with persistent chronic non-specific lower back pain, the pain symptoms of all 7 (100 %) improved, on average by 4.3 points (65.3 %) on the NRS.58

4.2. Other medications for chronic pain

Risperidone53 and aripiprazole59 are also said to be helpful for chronic pain.

Tricyclic antidepressants have long been the most important drugs for the treatment of chronic neuropathic pain, but have high side effects.60 TCAs were also previously used to treat ADHD (especially imipramine).
Antiepileptic drugs such as gabapentin, carbamazepine and lamotrigine are also helpful.60 Due to the massive withdrawal side effects, which are similar to withdrawal from opioids or alcohol and often enough require hospitalization, gabapentin is recommended at best as a last resort and with special information about the associated problems.
Baclofen, mexiletine and clonidine can also be helpful for selected people with ADHD.60

5. Causal pathways for chronic pain, increased muscle tone and fibromyalgia

According to Stray, motor disinhibition and increased muscle tone in ADHD are directly associated with dysregulation of the dopamine and noradrenaline systems.61
It is fitting that the increased muscle tone in ADHD is reduced by methylphenidate62 and that a noradrenaline reuptake inhibitor (orphenadrine, Norflex®) serves as a skeletal muscle relaxant. Noradrenaline reuptake inhibitors are also used as ADHD medication (atomoxetine, viloxazine).

One study reports an increased sphingomyelin/ceramide ratio in patients with lower back pain63 (which is also a typical form of ADHD). The acid sphingomyelinase (ASM, sphingomyelin phosphodiesterase 1, encoded by the ADHD candidate gene SMPD1) Degrades sphingomyelin to ceramide. If sphingomyelin is high and ceramide is low, this indicates weak S-ASM. With this in mind, FIASMA (ASM inhibitors) such as amitriptyline could be detrimental and increase the risk of muscle tension. Whether this idea is supportive for ADHD remains to be seen

So far, pain sensitivity has only been researched in two model animals with ADHD:10

SHR, an animal model for ADHD, showed

  • weakened pain suppression (analgesia) in the event of harmful stimuli64
  • a decrease in noradrenaline in the posterior horn of the spinal cord in response to nociceptive stimuli. An increase would be normal.65 The decrease indicates reduced endogenous pain suppression (analgesia) in ADHD.10
  • showed more active noradrenaline synthesis under pain conditions65 SHR:
    • more noradrenaline synthesizing enzymes in the posterior horn of the spinal cord
    • higher extracellular noradrenaline levels in the posterior horn of the spinal cord
  • excessive noradrenaline synthesis in a pain-free state could cause overexpression of NET and downregulation of the α2A receptor. This could lead to decreased norepinephrine activity during NSIA and attenuated descending pain inhibition.10 SHR showed:
    • more noradrenaline transporters in the posterior horn of the spinal cord
    • fewer α2A receptors in the posterior horn of the spinal cord
  • Atomoxetine reduced sensitivity to pain65

6-hydroxydopamine (6-OHDA) mice, another ADHD animal model, showed66

  • as a sign of increased basic nociceptive sensitivity
    • increased licking of the hind legs in response to thermal or mechanical stimuli
    • increased sensitization to pathological inflammatory stimuli
  • in the lamina II of the posterior horn of the spinal cord were
    • the inhibitory synaptic connections remain unchanged
    • the excitatory compounds were significantly increased
      • this could promote pain sensitization
  • Pain sensitivity in 6-OHDA) mice is probably mediated by18
    • Α-adrenergic receptors
    • Β-adrenergic receptors
    • D2 receptors
    • D3 receptors
  • Increased spontaneous activity of the ACC-PI signaling pathway.66 The ACC-PI pathway (from the ACC to the posterior insula, PI) controls central sensitization mechanisms. ADHD-induced ACC-PI activity can increase or decrease pain sensitivity and possibly trigger hyperactivity (ergomania).10
    • Caused by sex-specific neuroinflammatory response to dopamine (DA) neuron loss by 6-OHDA67
      • Males: Dopamine loss triggered inflammation only in the ACC
        • Consequences:
          • Hyperactivity
          • No increased sensitivity to pain (no hyperalgesia)
      • Females: Dopamine loss triggered inflammation in the ACC-PI signaling pathway
        • Consequences:
          • No hyperactivity
          • Increased sensitivity to pain (hyperalgesia)
        • May explain why
          • Prevalence of fibromyalgia6869 70 71 and other pain disorders7273 is higher in women
          • Hyperactivity is less common in women
    • Increased ACC activity in response to mechanical stimulation of the contralateral hind limb66
      • Resulting in increased firing rate in second-order nociceptive neurons in the dorsal horn of the spinal cord
        • Thereby further lowering the pain threshold
    • Inhibition of the ACC-PI pathway suppressed the action potentials of the posterior horn and increased the pain threshold66
  • Atomoxetine could reduce sensitivity to pain18

See also Chronic pain and muscle tension in ADHD - neurophysiological correlates


  1. Stickley, Koyanagi, Takahashi, Kamio (2016): ADHD symptoms and pain among adults in England. Psychiatry Res. 2016 Dec 30;246:326-331. doi: 10.1016/j.psychres.2016.10.004.

  2. Brown PCM, Feldstein Ewing SW, Wilson AC (2025): ADHD (Attention-Deficit Hyperactivity Disorder) Symptoms Are Associated With Chronic Pain Interference: Results From a Prospective Cohort Study. Child Care Health Dev. 2025 Jan;51(1):e70016. doi: 10.1111/cch.70016. PMID: 39629884; PMCID: PMC12051463.

  3. Kasahara S, Yoshimoto T, Oka H, Sato N, Morita T, Niwa SI, Uchida K, Matsudaira K (2025): Correlation between attention deficit/hyperactivity disorder and chronic pain: a survey of adults in Japan. Sci Rep. 2025 Apr 16;15(1):13165. doi: 10.1038/s41598-025-95864-4. PMID: 40240787; PMCID: PMC12003818.

  4. Berggren SS, Bergman S, Almquist-Tangen G, Dahlgren J, Roswall J, Malmborg JS (2024): Frequent Pain is Common Among 10-11-Year-Old Children with Symptoms of Attention Deficit Hyperactivity Disorder. J Pain Res. 2024 Nov 19;17:3867-3879. doi: 10.2147/JPR.S472414. PMID: 39583198; PMCID: PMC11585263. n = 1.186

  5. Caverius U, Åkerblom S, Lexell J, Fischer MR (2025): Characteristics of Children With Persistent Pain and Their Parents in a Tertiary Interdisciplinary Pain Clinic. Paediatr Neonatal Pain. 2025 Apr 12;7(2):e70005. doi: 10.1002/pne2.70005. PMID: 40226841; PMCID: PMC11992596.

  6. Chambers CT, Dol J, Tutelman PR, Langley CL, Parker JA, Cormier BT, Macfarlane GJ, Jones GT, Chapman D, Proudfoot N, Grant A, Marianayagam J (2024): The prevalence of chronic pain in children and adolescents: a systematic review update and meta-analysis. Pain. 2024 Oct 1;165(10):2215-2234. doi: 10.1097/j.pain.0000000000003267. PMID: 38743558; PMCID: PMC11404345. METASTUDY

  7. Udal ABH, Stray LL, Stray T, Bertelsen TB, Pripp AH, Egeland J (2024): ADHD-pain: Characteristics of chronic pain and association with muscular dysregulation in adults with ADHD. Scand J Pain. 2024 Sep 9;24(1). doi: 10.1515/sjpain-2024-0015. PMID: 39253953.

  8. King S, Chambers CT, Huguet A, MacNevin RC, McGrath PJ, Parker L, MacDonald AJ (2011): The epidemiology of chronic pain in children and adolescents revisited: a systematic review. Pain. 2011 Dec;152(12):2729-2738. doi: 10.1016/j.pain.2011.07.016. PMID: 22078064.

  9. Asztély, Kopp, Gillberg, Waern, Bergman (2019): Chronic Pain And Health-Related Quality Of Life In Women With Autism And/Or ADHD: A Prospective Longitudinal Study. J Pain Res. 2019 Oct 18;12:2925-2932. doi: 10.2147/JPR.S212422. eCollection 2019.

  10. Kasahara S, Takahashi M, Suto T, Morita T, Obata H, Niwa SI (2025): Innovative therapeutic strategies using ADHD medications tailored to the behavioral characteristics of patients with chronic pain. Front Pharmacol. 2025 Feb 26;16:1500313. doi: 10.3389/fphar.2025.1500313. PMID: 40078279; PMCID: PMC11896983. REVIEW

  11. Pallanti S, Porta F, Salerno L (2021): Adult attention deficit hyperactivity disorder in patients with fibromyalgia syndrome: Assessment and disabilities. J Psychiatr Res. 2021 Apr;136:537-542. doi: 10.1016/j.jpsychires.2020.10.027. PMID: 33127072. n = 106

  12. Kasahara S, Niwa SI, Matsudaira K, Sato N, Oka H, Fujii T, Konno SI, Kikuchi SI, Yamada Y (2021): High Attention-Deficit/Hyperactivity Disorder Scale Scores Among Patients with Persistent Chronic Nonspecific Low Back Pain. Pain Physician. 2021 May;24(3):E299-E307. PMID: 33988951.

  13. Kasahara S, Kato Y, Takahashi K, Matsudaira K, Sato N, Fukuda KI, Toyofuku A, Niwa SI, Uchida K (2023): Improvement in persistent idiopathic facial pain with comorbid ADHD using the combination of a dopamine system stabilizer and psychostimulant: A case report. Clin Case Rep. 2023 Jun 19;11(6):e7552. doi: 10.1002/ccr3.7552. PMID: 37346882; PMCID: PMC10279936.

  14. Takahashi K, Kasahara S, Takahashi M, Morita T, Sato N, Momose T, Matsudaira K, Niwa SI, Uchida K, Handa T, Ichinohe T, Fukuda KI (2025): Recognition and treatment of attention deficit-hyperactivity disorder in patients with treatment-resistant burning mouth syndrome: a retrospective case study. Front Pain Res (Lausanne). 2025 Apr 23;6:1536584. doi: 10.3389/fpain.2025.1536584. PMID: 40337528; PMCID: PMC12055801.

  15. Gee TA, Weintraub NC, Lu D, Phelps CE, Navratilova E, Heien ML, Porreca F (2020): A pain-induced tonic hypodopaminergic state augments phasic dopamine release in the nucleus accumbens. Pain. 2020 Oct;161(10):2376-2384. doi: 10.1097/j.pain.0000000000001925. PMID: 32453137; PMCID: PMC7508893.

  16. Taylor AMW, Becker S, Schweinhardt P, Cahill C (2016): Mesolimbic dopamine signaling in acute and chronic pain: implications for motivation, analgesia, and addiction. Pain. 2016 Jun;157(6):1194-1198. doi: 10.1097/j.pain.0000000000000494. PMID: 26797678; PMCID: PMC4866581.

  17. Tiemann L, Heitmann H, Schulz E, Baumkötter J, Ploner M (2014): Dopamine precursor depletion influences pain affect rather than pain sensation. PLoS One. 2014 Apr 23;9(4):e96167. doi: 10.1371/journal.pone.0096167. PMID: 24760082; PMCID: PMC3997524.

  18. Sifeddine W, Ba-M’hamed S, Landry M, Bennis M (2023): Effect of atomoxetine on ADHD-pain hypersensitization comorbidity in 6-OHDA lesioned mice. Pharmacol Rep. 2023 Feb 14. doi: 10.1007/s43440-023-00459-3. PMID: 36787018.

  19. Treister R, Eisenberg E, Demeter N, Pud D (2015): Alterations in pain response are partially reversed by methylphenidate (Ritalin) in adults with attention deficit hyperactivity disorder (ADHD). Pain Pract. 2015 Jan;15(1):4-11. doi: 10.1111/papr.12129. PMID: 24134430.

  20. Burkey AR, Carstens E, Jasmin L (1999): Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception. J Neurosci. 1999 May 15;19(10):4169-79. doi: 10.1523/JNEUROSCI.19-10-04169.1999. PMID: 10234044; PMCID: PMC6782709.

  21. Li J, Ji YP, Qiao JT, Dafny N (1992): Suppression of nociceptive responses in parafascicular neurons by stimulation of substantia nigra: an analysis of related inhibitory pathways. Brain Res. 1992 Sep 18;591(1):109-15. doi: 10.1016/0006-8993(92)90984-h. PMID: 1446222.

  22. Baumeister AA, Anticich TG, Hawkins MF, Liter JC, Thibodeaux HF, Guillory EC (1988): Evidence that the substantia nigra is a component of the endogenous pain suppression system in the rat. Brain Res. 1988 Apr 26;447(1):116-21. doi: 10.1016/0006-8993(88)90971-7. PMID: 3382946.

  23. Juri C, Rodriguez-Oroz M, Obeso JA (2010): The pathophysiological basis of sensory disturbances in Parkinson’s disease. J Neurol Sci. 2010 Feb 15;289(1-2):60-5. doi: 10.1016/j.jns.2009.08.018. PMID: 19758602.

  24. Treister R, Pud D, Ebstein RP, Laiba E, Gershon E, Haddad M, Eisenberg E (2009): Associations between polymorphisms in dopamine neurotransmitter pathway genes and pain response in healthy humans. Pain. 2009 Dec 15;147(1-3):187-93. doi: 10.1016/j.pain.2009.09.001. PMID: 19796878.

  25. Battison EAJ, Brown PCM, Holley AL, Wilson AC (2023): Associations between Chronic Pain and Attention-Deficit Hyperactivity Disorder (ADHD) in Youth: A Scoping Review. Children (Basel). 2023 Jan 11;10(1):142. doi: 10.3390/children10010142. PMID: 36670692; PMCID: PMC9857366. REVIEW

  26. Kasahara S, Niwa SI, Matsudaira K, Sato N, Oka H, Yamada Y (2020): Attention-Deficit/Hyperactivity Disorder and Chronic Pain. Psychosom Med. 2020 Apr;82(3):346-347. doi: 10.1097/PSY.0000000000000789. PMID: 32251099.

  27. Mundal I, Schei J, Lydersen S, Thomsen PH, Nøvik TS, Kvitland LR (2024): Prevalence of chronic and multisite pain in adolescents and young adults with ADHD: a comparative study between clinical and general population samples (the HUNT study). Eur Child Adolesc Psychiatry. 2024 May;33(5):1433-1442. doi: 10.1007/s00787-023-02249-x. PMID: 37386203; PMCID: PMC11098922.

  28. Stray, Kristensen, Lomeland, Skorstad, Stray, Tønnessen (2013): Motor regulation problems and pain in adults diagnosed with ADHD. Behav Brain Funct. 2013 May 3;9:18. doi: 10.1186/1744-9081-9-18. PMID: 23642255; PMCID: PMC3652792.

  29. Merzon E, Magen E, Levy Y, Ashkenazi S, Manor I, Weizman A, Krone B, Faraone SV, Green I, Golan-Cohen A, Vinker S, Israel A (2024): Pain-Associated Diagnoses in Childhood Before the Diagnosis of Attention-Deficit/Hyperactivity Disorder: A Population-Based Study. Children (Basel). 2024 Nov 15;11(11):1388. doi: 10.3390/children11111388. PMID: 39594963; PMCID: PMC11593160. n = 56.268

  30. Kasahara S, Takahashi K, Matsudaira K, Sato N, Fukuda KI, Toyofuku A, Yoshikawa T, Kato Y, Niwa SI, Uchida K (2023): Diagnosis and treatment of intractable idiopathic orofacial pain with attention-deficit/hyperactivity disorder. Sci Rep. 2023 Jan 30;13(1):1678. doi: 10.1038/s41598-023-28931-3. PMID: 36717626; PMCID: PMC9887013.

  31. Salem H, Vivas D, Cao F, Kazimi IF, Teixeira AL, Zeni CP (2018): ADHD is associated with migraine: a systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2018 Mar;27(3):267-277. doi: 10.1007/s00787-017-1045-4. PMID: 28905127. REVIEW

  32. Arruda MA, Arruda R, Guidetti V, Bigal ME (2020): ADHD Is Comorbid to Migraine in Childhood: A Population-Based Study. J Atten Disord. 2020 May;24(7):990-1001. doi: 10.1177/1087054717710767. PMID: 28587507.

  33. Arruda MA, Guidetti V, Galli F, Albuquerque RC, Bigal ME (2010): Migraine, tension-type headache, and attention-deficit/hyperactivity disorder in childhood: a population-based study. Postgrad Med. 2010 Sep;122(5):18-26. doi: 10.3810/pgm.2010.09.2197. PMID: 20861584.

  34. Fil A, Cano-de-la-Cuerda R, Muñoz-Hellín E, Vela L, Ramiro-González M, Fernández-de-Las-Peñas C (2013): Pain in Parkinson disease: a review of the literature. Parkinsonism Relat Disord. 2013 Mar;19(3):285-94; discussion 285. doi: 10.1016/j.parkreldis.2012.11.009. PMID: 23246139.

  35. Thompson T, Gallop K, Correll CU, Carvalho AF, Veronese N, Wright E, Stubbs B (2017): Pain perception in Parkinson’s disease: A systematic review and meta-analysis of experimental studies. Ageing Res Rev. 2017 May;35:74-86. doi: 10.1016/j.arr.2017.01.005. PMID: 28179128.

  36. Cury RG, Galhardoni R, Fonoff ET, Perez Lloret S, Dos Santos Ghilardi MG, Barbosa ER, Teixeira MJ, Ciampi de Andrade D (2016): Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. Eur J Pain. 2016 Feb;20(2):151-65. doi: 10.1002/ejp.745. PMID: 26147660.

  37. Stubbs B, Thompson T, Acaster S, Vancampfort D, Gaughran F, Correll CU (2015): Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies. Pain. 2015 Nov;156(11):2121-2131. doi: 10.1097/j.pain.0000000000000304. PMID: 26207650. METASTUDIE

  38. Kasahara S, Niwa SI, Matsudaira K, Sato N, Oka H, Fujii T, Konno SI, Kikuchi SI, Yamada Y (2021): High Attention-Deficit/Hyperactivity Disorder Scale Scores Among Patients with Persistent Chronic Nonspecific Low Back Pain. Pain Physician. 2021 May;24(3):E299-E307. PMID: 33988951.}}) erklären in{{Udal ABH, Stray LL, Stray T, Bertelsen TB, Pripp AH, Egeland J (2024): ADHD-pain: Characteristics of chronic pain and association with muscular dysregulation in adults with ADHD. Scand J Pain. 2024 Sep 9;24(1). doi: 10.1515/sjpain-2024-0015. PMID: 39253953.

  39. Lakkadsha TM, Qureshi MI, Kovela RK, Saifee SS, Lalwani SS (2022): Efficacy of Single Stretching Session of Iliopsoas Using Proprioceptive Neuromuscular Facilitation Versus Muscle Energy Technique on Low Back Pain in Patients With Lumbar Hyper-Lordosis. Cureus. 2022 Aug 12;14(8):e27916. doi: 10.7759/cureus.27916. PMID: 36110466; PMCID: PMC9464355.

  40. García-Marín, Campos, Cuéllar-Partida, Medland, Kollins, Rentería (2021): Large-scale genetic investigation reveals genetic liability to multiple complex traits influencing a higher risk of ADHD. Sci Rep. 2021 Nov 19;11(1):22628. doi: 10.1038/s41598-021-01517-7. PMID: 34799595.

  41. Onda A, Onozato K, Kimura M (2022): Clinical features of neck and shoulder pain (Katakori) in Japanese hospital workers. Fukushima J Med Sci. 2022 Aug 18;68(2):79-87. doi: 10.5387/fms.2022-02. PMID: 35660659; PMCID: PMC9493333. n = 359

  42. Stray LL, Stray T, Iversen S, Ruud A, Ellertsen B (2009): Methylphenidate improves motor functions in children diagnosed with Hyperkinetic Disorder. Behav Brain Funct. 2009 May 13;5:21. doi: 10.1186/1744-9081-5-21. PMID: 19439096; PMCID: PMC2686715.

  43. Überall, M A, Maurer S. (2023): Niedrig dosiertes Naltrexon zur Behandlung der Fibromyalgie: Vom Paradoxon eines Opioidantagonisten in der Schmerztherapie. Schmerzmedizin, 39(3), 46–49. https://doi.org/10.1007/s00940-023-4162-9

  44. Yang J, Shin KM, Do A, Bierle DM, Abu Dabrh AM, Yin Z, Bauer BA, Mohabbat AB (2023): The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review. J Pain Res. 2023 Mar 21;16:1017-1023. doi: 10.2147/JPR.S395457. PMID: 36974308; PMCID: PMC10039621. METASTUDY, k = 9

  45. Vatvani AD, Patel P, Hariyanto TI, Yanto TA (2024): Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Korean J Pain. 2024 Oct 1;37(4):367-378. doi: 10.3344/kjp.24202. PMID: 39344363; PMCID: PMC11450306. METASTUDY, k = 4

  46. Partridge S, Quadt L, Bolton M, Eccles J, Thompson C, Colasanti A, Bremner S, Jones CI, Bruun KD, Van Marwijk H (2023): A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia. Heliyon. 2023 Apr 19;9(5):e15638. doi: 10.1016/j.heliyon.2023.e15638. PMID: 37206027; PMCID: PMC10189400. REVIEW

  47. Rassi-Mariani V, Barreto ESR, Antunes CR, Alencar VB, Falcão Lins-Kusterer LE, Azi LMTA, Kraychete DC (2024): The use of naltrexone in the treatment of chronic pain: a systematic review. Pain Manag. 2024;14(8):453-463. doi: 10.1080/17581869.2024.2401769. PMID: 39301937; PMCID: PMC11487945.

  48. See S, Ginzburg R (2008): Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70. PMID: 18711953. REVIEW

  49. Treister R, Eisenberg E, Demeter N, Pud D (2015): Alterations in pain response are partially reversed by methylphenidate (Ritalin) in adults with attention deficit hyperactivity disorder (ADHD). Pain Pract. 2015 Jan;15(1):4-11. doi: 10.1111/papr.12129. PMID: 24134430.

  50. Zain E, Sugimoto A, Egawa J, Someya T (2023): Case report: Methylphenidate improved chronic pain in an adult patient with attention deficit hyperactivity disorder. Front Psychiatry. 2023 Mar 10;14:1091399. doi: 10.3389/fpsyt.2023.1091399. PMID: 36970292; PMCID: PMC10038200.

  51. Kasahara S, Takahashi M, Takahashi K, Morita T, Matsudaira K, Sato N, Momose T, Niwa SI, Uchida K (2024): Case Report: Methylphenidate and venlafaxine improved abdominal nociplastic pain in an adult patient with attention deficit hyperactivity disorder, autism spectrum disorder, and comorbid major depression. Front Pain Res (Lausanne). 2024 Aug 21;5:1394131. doi: 10.3389/fpain.2024.1394131. PMID: 39234404; PMCID: PMC11371746.

  52. Kasahara S, Takahashi M, Morita T, Matsudaira K, Sato N, Momose T, Niwa SI, Uchida K (2023): Case report: Atomoxetine improves chronic pain with comorbid post-traumatic stress disorder and attention deficit hyperactivity disorder. Front Psychiatry. 2023 Aug 7;14:1221694. doi: 10.3389/fpsyt.2023.1221694. PMID: 37608999; PMCID: PMC10441107.

  53. Kasahara S, Takao C, Matsudaira K, Sato N, Tu TTH, Niwa SI, Uchida K, Toyofuku A (2022): Case report: Treatment of persistent atypical odontalgia with attention deficit hyperactivity disorder and autism spectrum disorder with risperidone and atomoxetine. Front Pain Res (Lausanne). 2022 Jul 22;3:926946. doi: 10.3389/fpain.2022.926946. PMID: 35935670; PMCID: PMC9353025.

  54. Kasahara S, Kato Y, Takahashi M, Matsudaira K, Sato N, Niwa SI, Momose T, Uchida K (2023): Case report: Remission of chronic low back pain and oral dysesthesia comorbid with attention deficit/hyperactivity disorder by treatment with atomoxetine and pramipexole. Front Pain Res (Lausanne). 2023 Jun 5;4:1159134. doi: 10.3389/fpain.2023.1159134. PMID: 37342213; PMCID: PMC10277465.

  55. Kasahara S, Kanda S, Takahashi M, Fujioka M, Morita T, Matsudaira K, Sato N, Hattori M, Momose T, Niwa SI, Uchida K (2023): Case Report: Guanfacine and methylphenidate improved chronic lower back pain in autosomal dominant polycystic kidney disease with comorbid attention deficit hyperactivity disorder and autism spectrum disorder. Front Pediatr. 2023 Nov 1;11:1283823. doi: 10.3389/fped.2023.1283823. PMID: 38027301; PMCID: PMC10646415.

  56. Ryan (2014): ADHD is Not a Four Letter Word: Drug Free Strategies for Managing the Gift that is ADHD, Seite 97

  57. Kasahara S, Matsudaira K, Sato N, Niwa SI (2022): Attention-Deficit/hyperactivity disorder and centralized pain: A review of the case of John F. Kennedy. Clin Case Rep. 2022 Oct 8;10(10):e6422. doi: 10.1002/ccr3.6422. PMID: 36245472; PMCID: PMC9547351.

  58. Kasahara S, Okamura Y, Matsudaira K, Oka H, Suzuki Y, Murakami Y, Tazawa T, Shimazaki H, Niwa S, Yamada Y (2017): Diagnosis and Treatment of Attention-Deficit Hyperactivity Disorder in Patients with Chronic Pain. Open Journal of Psychiatry, 7, 261-275. doi: 10.4236/ojpsych.2017.74023

  59. Kasahara S, Kunii Y, Mashiko H, Otani K, Konno S, Niwa S (2011): Four cases of chronic pain that improved dramatically following low-dose aripiprazole administration. Prim Care Companion CNS Disord. 2011;13(2):PCC.10l01078. doi: 10.4088/PCC.10l01078. PMID: 21977351; PMCID: PMC3184588.

  60. Guay DR (2001): Adjunctive agents in the management of chronic pain. Pharmacotherapy. 2001 Sep;21(9):1070-81. doi: 10.1592/phco.21.13.1070.34622. PMID: 11560197. REVIEW

  61. Stray (2009): Motor problems in Children with ADHD and clinical effects of Methylphenidate as assessed with the MFNU. Dissertation.

  62. Stray, Stray, Iversen, Ruud, Ellertsen (2009): Methylphenidate improves motor functions in children diagnosed with Hyperkinetic Disorder. Behav Brain Funct. 2009 May 13;5:21. doi: 10.1186/1744-9081-5-21. PMID: 19439096; PMCID: PMC2686715.

  63. Zhang Z, Zhang C, Li Y, Wang C, Yu Q (2022): Lipid and metabolic alteration involvement in physiotherapy for chronic nonspecific low back pain. Lipids Health Dis. 2022 Nov 25;21(1):125. doi: 10.1186/s12944-022-01737-4. PMID: 36434687; PMCID: PMC9700977.

  64. Tambeli CH, Levine JD, Gear RW (2009): Centralization of noxious stimulus-induced analgesia (NSIA) is related to activity at inhibitory synapses in the spinal cord. Pain. 2009 Jun;143(3):228-232. doi: 10.1016/j.pain.2009.03.005. PMID: 19375225; PMCID: PMC2693265.

  65. Suto T, Kato D, Koibuchi I, Arai Y, Ohta J, Hiroki T, Obata H, Saito S (2023): Rat model of attention-deficit hyperactivity disorder exhibits delayed recovery from acute incisional pain due to impaired descending noradrenergic inhibition. Sci Rep. 2023 Apr 4;13(1):5526. doi: 10.1038/s41598-023-32512-9. PMID: 37016045; PMCID: PMC10073110.

  66. Bouchatta O, Aby F, Sifeddine W, Bouali-Benazzouz R, Brochoire L, Manouze H, Fossat P, Ba M’Hamed S, Bennis M, Landry M (2022): Pain hypersensitivity in a pharmacological mouse model of attention-deficit/hyperactivity disorder. Proc Natl Acad Sci U S A. 2022 Jul 26;119(30):e2114094119. doi: 10.1073/pnas.2114094119. PMID: 35858441; PMCID: PMC9335339.

  67. Meseguer-Beltrán M, Sánchez-Sarasúa S, Landry M, Kerekes N, Sánchez-Pérez AM (2023): Targeting Neuroinflammation with Abscisic Acid Reduces Pain Sensitivity in Females and Hyperactivity in Males of an ADHD Mice Model. Cells. 2023 Jan 31;12(3):465. doi: 10.3390/cells12030465. PMID: 36766806; PMCID: PMC9914171.

  68. Marques AP, Santo ASDE, Berssaneti AA, Matsutani LA, Yuan SLK (2017): Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol Engl Ed. 2017 Jul-Aug;57(4):356-363. English, Portuguese. doi: 10.1016/j.rbre.2017.01.005. PMID: 28743363. REVIEW

  69. Martínez-Lavín M (2021): Fibromyalgia in women: somatisation or stress-evoked, sex-dimorphic neuropathic pain? Clin Exp Rheumatol. 2021 Mar-Apr;39(2):422-425. doi: 10.55563/clinexprheumatol/0c7d6v. Epub 2020 Sep 16. PMID: 32940205. REVIEW

  70. Queiroz LP (2013): Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 2013 Aug;17(8):356. doi: 10.1007/s11916-013-0356-5. PMID: 23801009. REVIEW

  71. Wolfe F, Walitt B, Perrot S, Rasker JJ, Häuser W (2018): Fibromyalgia diagnosis and biased assessment: Sex, prevalence and bias. PLoS One. 2018 Sep 13;13(9):e0203755. doi: 10.1371/journal.pone.0203755. PMID: 30212526; PMCID: PMC6136749.

  72. Bartley EJ, Fillingim RB (2013): Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth. 2013 Jul;111(1):52-8. doi: 10.1093/bja/aet127. PMID: 23794645; PMCID: PMC3690315. REVIEW

  73. Pieretti S, Di Giannuario A, Di Giovannandrea R, Marzoli F, Piccaro G, Minosi P, Aloisi AM (2016): Gender differences in pain and its relief. Ann Ist Super Sanita. 2016 Apr-Jun;52(2):184-9. doi: 10.4415/ANN_16_02_09. PMID: 27364392. REVIEW

Diese Seite wurde am 05.11.2025 zuletzt aktualisiert.